BACKGROUND: The current single-arm, open-label trial was designed to evaluate the activity of apitolisib (GDC-0980), a dual phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor, in patients with advanced endometrial cancer (EC). METHODS: Patients with recurrent or persistent EC who were treated with 1 to 2 prior lines of chemotherapy but no prior PI3K/mTOR inhibitor received oral apitolisib at a dose of 40 mg daily during 28-day cycles until disease progression or intolerable toxicity occurred. Patients with type I/II diabetes who required insulin were excluded. The primary endpoints were progression-free survival (PFS) at 6 months and objective response rate. RESULTS: A total of 56 women were enrolled, including 13 (23%) with well-controlled diabetes. Reasons for discontinuation were disease progression (24 patients; 43%), adverse events (13 patients; 23%), and withdrawal by subject (12 patients; 21%). Grade 3/4 apitolisib-related adverse events were hyperglycemia (46%), rash (30%), colitis (5%), and pneumonitis (4%) (toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]). The PFS rate at 6 months was 20% (Kaplan-Meier estimate; 95% confidence interval [95% CI], 7%-33%). The objective response rate was 6% (confirmed). The median PFS was 3.5 months (95% CI, 2.7-3.7 months) and the median overall survival was 15.7 months (95% CI, 9.2-17.0 months). Nineteen patients discontinued the study before the first tumor assessment. Dose reductions were required for 4 diabetic (31%) and 18 nondiabetic (42%) patients. Comprehensive molecular profiling of 46 evaluable archival tumor samples demonstrated that 57% of patients had at least 1 alteration in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphatase and tensin homolog (PTEN), or AKT1. All 3 patients with a confirmed response had at least 1 alteration in a PI3K pathway gene. CONCLUSIONS: The antitumor activity noted with the use of a dose of 40 mg of apitolisib daily was limited by tolerability, especially in diabetic patients. Patients with PI3K pathway mutations may have derived enhanced benefit from apitolisib. Cancer 2016;122:3519-28.
BACKGROUND: The current single-arm, open-label trial was designed to evaluate the activity of apitolisib (GDC-0980), a dual phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) inhibitor, in patients with advanced endometrial cancer (EC). METHODS:Patients with recurrent or persistent EC who were treated with 1 to 2 prior lines of chemotherapy but no prior PI3K/mTOR inhibitor received oral apitolisib at a dose of 40 mg daily during 28-day cycles until disease progression or intolerable toxicity occurred. Patients with type I/II diabetes who required insulin were excluded. The primary endpoints were progression-free survival (PFS) at 6 months and objective response rate. RESULTS: A total of 56 women were enrolled, including 13 (23%) with well-controlled diabetes. Reasons for discontinuation were disease progression (24 patients; 43%), adverse events (13 patients; 23%), and withdrawal by subject (12 patients; 21%). Grade 3/4 apitolisib-related adverse events were hyperglycemia (46%), rash (30%), colitis (5%), and pneumonitis (4%) (toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events [version 4.0]). The PFS rate at 6 months was 20% (Kaplan-Meier estimate; 95% confidence interval [95% CI], 7%-33%). The objective response rate was 6% (confirmed). The median PFS was 3.5 months (95% CI, 2.7-3.7 months) and the median overall survival was 15.7 months (95% CI, 9.2-17.0 months). Nineteen patients discontinued the study before the first tumor assessment. Dose reductions were required for 4 diabetic (31%) and 18 nondiabetic (42%) patients. Comprehensive molecular profiling of 46 evaluable archival tumor samples demonstrated that 57% of patients had at least 1 alteration in phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), phosphatase and tensin homolog (PTEN), or AKT1. All 3 patients with a confirmed response had at least 1 alteration in a PI3K pathway gene. CONCLUSIONS: The antitumor activity noted with the use of a dose of 40 mg of apitolisib daily was limited by tolerability, especially in diabeticpatients. Patients with PI3K pathway mutations may have derived enhanced benefit from apitolisib. Cancer 2016;122:3519-28.
Authors: Lydia W T Cheung; Bryan T Hennessy; Jie Li; Shuangxing Yu; Andrea P Myers; Bojana Djordjevic; Yiling Lu; Katherine Stemke-Hale; Mary D Dyer; Fan Zhang; Zhenlin Ju; Lewis C Cantley; Steven E Scherer; Han Liang; Karen H Lu; Russell R Broaddus; Gordon B Mills Journal: Cancer Discov Date: 2011-06-07 Impact factor: 39.397
Authors: Brian M Slomovitz; Yunyun Jiang; Melinda S Yates; Pamela T Soliman; Taren Johnston; Maureen Nowakowski; Charles Levenback; Qian Zhang; Kari Ring; Mark F Munsell; David M Gershenson; Karen H Lu; Robert L Coleman Journal: J Clin Oncol Date: 2015-01-26 Impact factor: 44.544
Authors: Brian M Slomovitz; Karen H Lu; Taren Johnston; Robert L Coleman; Mark Munsell; Russell R Broaddus; Cheryl Walker; Lois M Ramondetta; Thomas W Burke; David M Gershenson; Judith Wolf Journal: Cancer Date: 2010-08-02 Impact factor: 6.860
Authors: Carol Aghajanian; Michael W Sill; Kathleen M Darcy; Benjamin Greer; D Scott McMeekin; Peter G Rose; Jacob Rotmensch; Mack N Barnes; Parviz Hanjani; Kimberly K Leslie Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Robert L Coleman; Michael W Sill; Heather A Lankes; Amanda Nickles Fader; Neil J Finkler; James S Hoffman; Peter G Rose; Gregory P Sutton; Charles W Drescher; D Scott McMeekin; Wei Hu; Michael Deavers; Andrew K Godwin; R Katherine Alpaugh; Anil K Sood Journal: Gynecol Oncol Date: 2012-08-23 Impact factor: 5.482
Authors: Jill M Spoerke; Carol O'Brien; Ling Huw; Hartmut Koeppen; Jane Fridlyand; Rainer K Brachmann; Peter M Haverty; Ajay Pandita; Sankar Mohan; Deepak Sampath; Lori S Friedman; Leanne Ross; Garret M Hampton; Lukas C Amler; David S Shames; Mark R Lackner Journal: Clin Cancer Res Date: 2012-11-07 Impact factor: 12.531
Authors: Taoda Shi; Christopher J Zerio; Jared Sivinski; Andrew J Ambrose; Kohlson T Moore; Thomas Buckley; Lynn Kaneko; Mae Zhang; Donna D Zhang; Eli Chapman Journal: European J Org Chem Date: 2019-04-30
Authors: Andrew D Cherniack; Hui Shen; Vonn Walter; Chip Stewart; Bradley A Murray; Reanne Bowlby; Xin Hu; Shiyun Ling; Robert A Soslow; Russell R Broaddus; Rosemary E Zuna; Gordon Robertson; Peter W Laird; Raju Kucherlapati; Gordon B Mills; John N Weinstein; Jiashan Zhang; Rehan Akbani; Douglas A Levine Journal: Cancer Cell Date: 2017-03-13 Impact factor: 31.743
Authors: Andrea P Myers; Panagiotis A Konstantinopoulos; William T Barry; Weixiu Luo; Russell R Broaddus; Vicky Makker; Ronny Drapkin; Joyce Liu; Austin Doyle; Neil S Horowitz; Funda Meric-Bernstam; Michael Birrer; Carol Aghajanian; Robert L Coleman; Gordon B Mills; Lewis C Cantley; Ursula A Matulonis; Shannon N Westin Journal: Int J Cancer Date: 2019-12-13 Impact factor: 7.396
Authors: Maria M Rubinstein; David M Hyman; Imogen Caird; Helen Won; Krysten Soldan; Kenneth Seier; Alexia Iasonos; William P Tew; Roisin E O'Cearbhaill; Rachel N Grisham; Martee L Hensley; Tiffany Troso-Sandoval; Paul Sabbatini; Joyce Guillen; S Duygu Selcuklu; Catherine Zimel; Jean Torrisi; Carol Aghajanian; Vicky Makker Journal: Cancer Date: 2019-12-27 Impact factor: 6.860